Safrel Pharmaceuticals Receives FDA Warning Letter Citing Quality Unit Collapse Across OTC Drug Operations

Safrel Pharmaceuticals LLC's FDA Warning Letter, issued August 7, 2026, exposes a quality system operating without a functional quality unit, no Certificates of Analysis, no supplier quality agreements, and no written procedures governing receipt, quarantine, or distribution of OTC drug products, conditions that render its products adulterated under 21 CFR Parts 210 and 211.

FDA investigators inspecting the Dayton, New Jersey facility between January 13 and January 30, 2026, found that Safrel held, labeled, released, and distributed OTC products under its own label while performing no quality unit oversight of suppliers or contract manufacturers, including packagers. The firm did not request, receive, or maintain CoAs for incoming bulk or finished drug products. One named contract manufacturer had already accumulated a record of CGMP noncompliance across multiple FDA inspections, a supplier risk that Safrel's absent qualification program left undetected and unmanaged.

Warehouse controls compounded the exposure. Finished drug products marked "Unlabeled, No Lot, No Exp" were stored in the same general area as labeled product, with no written procedures governing receipt, pre-release quarantine, storage conditions, or distribution authorization, a concurrent violation of 21 CFR 211.42. No lot distribution traceability system existed to support a recall, should one be required.

Safrel's February 22, 2026, response to the Form FDA 483 described a newly established quality unit, a quality manual, and revised SOPs. FDA rejected the response as inadequate on multiple grounds: no comprehensive assessment of the QU's actual current capabilities, no evaluation of quality impact on already-distributed product, and insufficient detail on how incoming drug products will be verified against quality specifications or how CGMP noncompliance by contract manufacturers will be detected and monitored going forward. The systemic nature of the failures, FDA noted, was not addressed.

For QA directors and regulatory leads at OTC drug distributors, the letter functions as a direct benchmark. The cited deficiencies, absent quality agreements, no CoA program, unqualified contract manufacturers, and uncontrolled warehousing, represent the minimum infrastructure 21 CFR 211.22 requires before any lot reaches distribution. The FDA's explicit rejection of Safrel's post-inspection response signals that procedural commitments, without demonstrated capability and retrospective impact assessment, will not satisfy the agency.

The adequacy of Safrel's corrective actions, including its supplier qualification program and quality agreement execution timeline, will be the measurable checkpoint against which any subsequent FDA re-inspection will be assessed.

Source: FDA Center for Drug Evaluation and Research (CDER) via FDA.gov Warning Letters, August 18, 2026. Reference #320-26-111; inspection dates January 13–30, 2026.